Research programme: high mobility group box chromosomal protein-1 inhibitors - Nautilus/Sienna Biopharmaceuticals
Alternative Names: CT500 variant - Nautilus/Sienna Biopharmaceuticals; HMGB-1 inhibitors - Nautilus/Sienna Biopharmaceuticals; Improved CT500Latest Information Update: 15 Dec 2016
Price :
$50 *
At a glance
- Originator Creabilis Therapeutics; Nautilus Biotech
- Class Proteins
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis; Sepsis